Skip to main content
. 2020 Nov 25;21(23):8948. doi: 10.3390/ijms21238948

Figure 3.

Figure 3

Overview of Tau immunotherapies in clinical trial. Indicated are passive and active Tau immunotherapy agents that have reached clinical trials Phase 1/2, for binding both intra and extracellular Tau in the CNS. The Roche RG7345 antibody has since been discontinued (Clinicaltrials.gov). Key: conform. -dep. refers to conformation-dependent antibody recognition of Tau, 16x means 16 Tau fragments repeats, and eTau refers to extracellular Tau.